These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1057355)

  • 1. Chemotherapy of malignant lymphomas.
    Stacher A
    Acta Neuropathol Suppl; 1975; Suppl 6():221-5. PubMed ID: 1057355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of advanced malignant lymphomas comparative evaluation of results with single agent and combination therapy.
    Klener P; Donner L; Roth Z
    Neoplasma; 1976; 23(3):315-22. PubMed ID: 958533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer; 1983 Apr; 51(8):1348-52. PubMed ID: 6186356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable outcome of central nervous system toxoplasmosis occurring in a patient with untreated Hodgkin's disease.
    Green JA; Spruance SL; Cheson BD
    Cancer; 1980 Feb; 45(4):808-10. PubMed ID: 7357497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Salvage chemotherapy in resistant malignant lymphomas (author's transl)].
    Tursz T; Ben Ayed F; Droz JP; Spielmann M; Amiel JL
    Bull Cancer; 1982; 69(1):28-32. PubMed ID: 6176284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy program for treatment of Hodgkin's disease refractory to MOPP or MVPP].
    Armata J
    Pol Tyg Lek; 1977 Sep; 32(37):1441-3. PubMed ID: 71724
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of nitrosourea derivatives in the treatment of patients with Hodgkin's disease with lesions of the central nervous system].
    Gershanovich ML; Arkhipov AI; Vilenskiĭ BS
    Vopr Onkol; 1988; 34(5):542-9. PubMed ID: 3381494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.
    Bonadonna G; Zucali R; Monfardini S; De Lena M; Uslenghi C
    Cancer; 1975 Jul; 36(1):252-9. PubMed ID: 54209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
    Rodgers RW; Gamble JF; Loh KK; Shullenberger CC
    Cancer; 1980 Dec; 46(11):2349-55. PubMed ID: 6159961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).
    Sutcliffe SB; Wrigley PF; Stansfeld AG; Malpas JS
    Cancer Chemother Pharmacol; 1979; 2(3):209-13. PubMed ID: 88280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Santoro A; Bonadonna G
    Cancer Chemother Pharmacol; 1979; 2(2):101-5. PubMed ID: 93984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of malignant lymphomas.
    Bonadonna G
    Semin Oncol; 1985 Dec; 12(4 Suppl 6):1-14. PubMed ID: 2417334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of malignant lymphomas].
    Huber H; Gattringer C; Lechleitner M; Gyenes T; Frommhold H; Brittinger G; Braunsteiner H
    Wien Klin Wochenschr; 1983 Feb; 95(4):93-112. PubMed ID: 6342274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of Hodgkin's disease.
    Malpas JS
    J R Coll Physicians Lond; 1980 Jan; 14(1):26-33. PubMed ID: 6160241
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Papa G; Mandelli F; Anselmo AP; De Luca AM; Maurizienrici R; Mauro F; Testi AM; Amadori S; Biagini C
    Eur J Cancer Clin Oncol; 1982 Sep; 18(9):803-6. PubMed ID: 6185342
    [No Abstract]   [Full Text] [Related]  

  • 20. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
    Santoro A; Bonfante V; Bonadonna G
    Ann Intern Med; 1982 Feb; 96(2):139-43. PubMed ID: 6174060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.